AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback